Search
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalNeisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by
Typhoid Vi polysaccharide vaccine
go.drugbank.com/drugs/DB10803ApprovedInvestigationalIt is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnIt was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow.
Sodium citrate
go.drugbank.com/drugs/DB09154ApprovedInvestigationalIt works by neutralizing excess acid in the blood and urine. It has been indicated for the treatment of metabolic acidosis.
Citric acid
go.drugbank.com/drugs/DB04272ApprovedInvestigationalNutraceuticalVet approvedCitric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalIt is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Cipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigationalCipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated … [L63809] Haisco began its development in 2012 by adding a chiral cyclopropyl group to the alkylphenol scaffold, with the stated aim of retaining the rapid onset and complete recovery expected of this class
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigational[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalEncorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by